The discriminator inside Bridge is not how sick a patient is. It is whether the FDA has already approved a GLP-1 for the condition on the chart. Prediabetes at a BMI of 27 to 34 is a ticket in [5]. Type 2 diabetes sends the patient back to a Part D plan where copays can run into the hundreds per month [6]. The sorting is done by the label, not by the need.
That has a consequence nobody has to legislate: because the exclusion is keyed to FDA approval, every new indication a manufacturer wins moves patients out of the $50 lane and into cost sharing [6]. Jeff La Marca is the worked example. At a BMI of 42 he clears the weight threshold on its own [5][10], and it is the severe obstructive sleep apnea, the diagnosis that most plainly justifies the prescription, that got his application denied [9]. The rejection notice did not tell him that [9].
The cost scenarios from KFF's Juliette Cubanski are usually read as a range of budget exposure. Divided out, they price the purchase. A quarter of 3.8 million eligible people is 950,000, and $3.3 billion spread across them over 18 months is about $3,474 each, or roughly $193 a month to Medicare [1]. The three-quarters case lands within two dollars a month of the same number [2]. Add the beneficiary's $50 and the implied all-in price is about $243 a month, close to a third of the $750 cash price La Marca was quoted in January [3][8]. It is a bulk purchase at a steep discount, and the discount only reaches the patients the program admits.
Against that, the reporting coming out of CMS measures throughput. Spokesperson Timothy Foster cites prior authorizations mostly cleared in under 12 hours and thousands of beneficiaries filling prescriptions at pharmacies [14]. One percent of the eligible pool is 38,000 people, so a count still described in thousands sits under a point of penetration [5]. The federal government has not published an uptake or cost estimate of its own [15], which leaves Cubanski's quarter-enrollment case as the working assumption, and that case already assumes three of every four eligible people never sign up [12].
The population arithmetic sets the ceiling. Bridge's 3.8 million is 39 percent of the 9.7 million you get once you add the 5.9 million overweight beneficiaries already eligible for GLP-1s through Part D [4][13]. The rest are covered in the sense Taylor Lacy, a primary care physician in Roeland Park, Kansas, means when she says coverage does not always mean affordable [18]. Appetite is not the binding constraint here; about one in five American adults has taken a GLP-1 and most, insured included, say the drugs are hard to afford [17]. Bridge fixes the price for the group with no FDA-recognised indication, and leaves the copay where it was for the patients whose diagnoses the agency has already accepted as reasons to prescribe [6].
